Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2003

View Archived Issues

Clinical benefits of efalizumab in plaque-type psoriasis

Good efficacy and safety profile reported for arzoxifene in hormone-sensitive breast cancer

New NK1 antagonists identified by Kyorin researchers

Novartis presents new PTP1B inhibitors in a recent patent

Spanish researchers prepare and test novel cannabinoid CB1 antagonists

Sumitomo claims TGF-beta antagonists with potential in fibrotic disorders

New EGFR inhibitors discovered at Boehringer Ingelheim

Ono claims novel prostanoid DP antagonists, their preparation and use

Pfizer scientists describe novel PPARgamma ligands and their use

Phase I trial begins for ChimeriVax-West Nile vaccine

Gene expression profiling for classifying pediatric ALL

Candidate gene for obesity located by international research team

Parkinson's disease: important genetic findings and RNAi-based drug development

Final results for phase II study of R-1549 in gastric cancer

Positive long-term data obtained for Aryplase

Rat study results for injectable sustained-release ZT-1 for Alzheimer's disease

Green light for phase I/II study of Enzo's gene vector for HIV

Guilford announces positive phase II results for Aquavan

Completion of first clinical study of Durect's postoperative pain depot product

Edaravone has beneficial effects in LPS-induced liver damage

Sativex marketing agreement extended to Canada

Shire and Noven work towards MethyPatch approval

Xcytrin evaluated in combination with Rituxan and Zevalin

Intranasal QR-435 prevents influenza infection in ferrets

Spotlight on systemic lupus erythematosus

Neuroprotective efficacy of neurosteroid in spinal cord ischemia

VP-025 prevents LPS-induced LTP impairment in rat brain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...